ClinicalTrials.gg
CompletedNCT03629925Updated Feb 28, 2023Results posted

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

A Phase 3 interventional study of Sintilimab and Gemcitabine in Squamous NSCLC, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Efficacy and Safety Evaluation of IBI308 in Patients with Advanced or Recurrent Squamous NSCLC

Read the detailed description

The anti-tumor activity of anti-PD-1 therapy in previously untreated Chinese squamous NSCLC patients will be investigated in this clinical trial.

02

Conditions studied

  • Squamous NSCLC
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must sign written ICF prior tothe implementation of any procedures related to the study;
  2. Aged ≥ 18 years and ≤ 75 years;
  3. With a of more than 3 months;
  4. With at least one confirmed by the investigator according to v1.1.

    Measurable lesions locatedin the field of previous radiotherapy or locoregional therapy canbe selected as target lesions if PD is confirmed;

  5. Participants with or cytologically confirmed locally advanced (stage IIIB/IIIC) who are ineligible for radical surgery or concurrent chemoradiotherapy, (stage IV)or recurrent squamous NSCLC based on the "8th Edition of the TNM Classification for LungCancer" issued by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer Classification;
  6. With an PS score of 0 or 1;
  7. Have not received any prior systemic anti-tumor therapy for advanced/metastatic disease; for participants who have received prior platinum-based chemotherapy/radiotherapy,neoadjuvant chemotherapy/radiotherapy, or radical chemoradiotherapy, they are eligible for the study if PD occurs at > 6 months after the last treatment;
  8. With adequate hematologic function, defined as ≥ 1.5 × 10\^9/L, count ≥ 100 × 10\^9/L, and ≥ 90 g/L (noblood transfusion history within 7 days);
  9. Adequate hepatic function, defined as ≤ 1.5 × and as well as ALT ≤ 2.5 × ULN for all participants, or AST and ALT ≤ 5 × ULN for participants with liver metastasis;
  10. Adequate renal function, defined as CCr ≥ 50 mL/min ( formula);
  11. Adequate coagulation function, defined as or PT ≤ 1.5 × ULN; for the participant who is receiving anticoagulant therapy, INR or PT within the proposed scope of the anticoagulantmedication is acceptable;
  12. Female participants of childbearing age should be tested negative for urine or serum pregnancy within 3 days before the first dose of the study treatments. A blood pregnancy testis required if the urine pregnancy test is inconclusive;
  13. For male and female participants with conception potential, highly effective measures (failure rate \< 1% per year) should be taken until at least 180 days afterdiscontinuation of the study treatment;

Note: Abstinence is acceptable as a method of contraception if it is the usual lifestyle and preferred method of contraception for the participant.

Exclusion criteria

Exclusion Criteria:

  1. Histological type of nonsquamousNSCLC. The dominant cell morphology must be identified for mixed cell type (participants with squamous cell carcinoma components > 50% can beenrolled); participants with small cell carcinoma, neuroendocrine carcinoma, and sarcoma components cannot be included;
  2. Participants with known EGFR-sensitive mutations or ALK rearrangement;
  3. Currently participating in an interventional clinical study, or treated with another study drug therapy or device therapy within 4 weeks before the first dose;
  4. Previously received the following therapies: , anti-PD-L1, or anti-PD-L2 agents or agents targeting another stimulation or synergistically inhibiting TCR (e.g., CTLA-4, OX-40,and CD137);
  5. Received proprietary Chinese medicines with anti-tumor indications or immunomodulators (thymosin, interferon, interleukin, etc.) within 2 weeks prior to the first dose, or received a major surgery within 3 weeks prior to the first dose;
  6. With active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction, and peritoneal requiring clinical intervention;
  7. Have undergone solid organ transplantation or hematologic transplantation;
  8. With clinically uncontrolled pleural effusion/ascites (participants who do not need effusion drainage or have no significant increase in effusion within 3 days after stopping drainage canbe enrolled);
  9. With a tumor compressing the surrounding important organs (such as esophagus) with relevant symptoms, compressing the superior vena cava, or invading the mediastinal great vessels,heart, etc.;
  10. With Class III-IV congestive cardiac failure (based on Classification) or poorly controlled and arrhythmia;
  11. With any arterial thrombosis, embolism, or ischemia within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemicattack. With a history of deep venous thrombosis, pulmonary embolism, or any other seriousthromboembolic events within 3 months priorto enrollment (implantable port or catheter-related thrombosis, or superficial venous thrombosis is not considered as "serious"thromboembolism);
  12. With known allergy to the active ingredients and/or any of sintilimab , gemcitabine, cisplatin, orcarboplatin;
  13. With active disease requiring systemic treatment (e.g., use of disease-modifying drugs, , or agents) within 2 years before the first dose.Replacement therapy (e.g., thyroxine, insulin, or physiologic doses of corticosteroids foradrenal or pituitary insufficiency) is not considered systemic;
  14. Participants requiring long-term systemic use of corticosteroids. Participants requiring intermittent use of bronchodilators, inhaled corticosteroids, or localinjection ofcorticosteroids for or asthma can be included in the study;
  15. Full recovery (i.e., ≤ Grade 1 or reaching the baseline, excluding asthenia or alopecia) from toxicity and/or complications caused by any intervention has not achieved before thestart oftreatment;
  16. Diagnosed with other malignant tumors within 5 years before the first dose, excluding radically cured cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and/orradically resected carcinoma in situ. For other malignant tumors or lung cancer diagnosedmore than 5 years before the first dose, pathological or cytological diagnosis should beperformed for recurrent and metastatic lesions;
  17. Symptomatic . Participants with asymptomatic brain metastases or with stable symptoms after treatment of brain metastases are allowed to participate in this study as longas meeting all of the following criteria: presence of outside the CNS;absence of metastases in midbrain, pons, cerebellum, meninges, medulla oblongata, or spinalcord; maintain clinical stable condition for at least 2 weeks; discontinue hormone therapy 14 days prior to the first dose of the study treatments;
  18. With a history of non-infectious pneumonia requiring corticosteroid therapy within 1year prior to the first dose or with non-infectious pneumonia at present;
  19. With an active infection requiring treatment or have used systemic anti-infective drugs within one week prior to the first dose;
  20. With known psychiatric disorder or substance abuse that could affect the compliance with study requirements;
  21. Known history of infection (i.e. HIV 1/2 antibody positive), known syphilis infection (syphilis antibody positive), or active tuberculosis;
  22. With untreated active ;

    Note: Participants with hepatitis B who meet the following criteria are also eligible forinclusion:

    HBV viral load must be less than 1000 copies/mL (200 IU/mL) or below LLD prior to thefirst dose, and participants should receive anti-HBV treatment to avoid virus reactivation throughout the therapeutic phase of the study; For participants with HBcAb (+), HBsAg (-), HBsAb (-), and HBV load (-), close monitoring is required instead of prophylactic anti-HBV treatment to avoid virus reactivation;

  23. Participants with active infection (HCV antibody positive and HCV-RNA level above the LLD);
  24. Have received within 30 days prior to the first dose; Note: Seasonal inactivated influenza virus vaccines for injection are allowed, while liveattenuated influenza vaccines forintranasal use are not acceptable;
  25. With any medical history, disease, treatment, or laboratory abnormal finding that would interfere with the study results or prevent the participant from participating in the whole study,or the investigator believes that participation in this study is not in the best interest of theparticipant;
  26. With local or systemic diseases not attributing to , or with cancer-related secondary diseases, which would result in a high medical risk and/or uncertainty in survivalevaluation
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    Sintilimab+ gemcitabine plus platinum

    Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin

    Drug: Sintilimab · Drug: Gemcitabine · Drug: Cisplatin · Drug: Carboplatin

  • Placebo comparator
    Placebo+gemcitabine plus platinum

    Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Placebo · Drug: Carboplatin

Interventions

  • 200mg, Q3W, day1, I.V.; consecutive cycles

    Also known as: IBI308

  • 1000mg/m\^2, Q3W, day 1and 8, I.V.; first 4 or 6 consecutive cycles.

  • 75 mg/m\^2, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.

  • DrugPlacebo

    NA, Q3W, day1, I.V.; consecutive cycles

  • AUC 5mg/ml/min, Q3W, day1, I.V.; first 4 or 6 consecutive cycles.

06

What researchers measure

Primary outcomes

  1. PFS(Progression Free Survival)

    PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS according to RECIST 1.1 as assessed by BIRRC was reported for each arm.

    Time frame: Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)

Secondary outcomes

  1. OS (Overall Survival)

    OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. OS was reported for each arm.

    Time frame: Through Database Cutoff Date of 15 October 2019 (up to approximately 13 months)

  2. ORR(Objective Response Rate)

    ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by BIRRC was reported as the ORR for each arm.

    Time frame: Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)

  3. TTR (Time to Response)

    TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The time from first treatment administration to the first incidence of treatment response was reported as the TTR for each arm.

    Time frame: Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)

  4. DCR (Disease Control Rate)

    DCR was defined as the percentage of participants who had a CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD\]). The percentage of participants who experienced a confirmed CR, PR, or SD according to RECIST 1.1 as assessed by BIRRC was reported as the DCR for each arm.

    Time frame: Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)

  5. DOR (Duration of Response)

    For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BIRRC assessment. The DOR according to RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported for each arm.

    Time frame: Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)

07

Results

Posted Apr 1, 2021

Participant flow

primary analysis data cutoff date: 15 October 2019; updated analysis data cutoff date: 25 March 2020

Participant flow — Overall Study
MilestoneSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
Started179178
Completed00
Not completed179178

Outcome measures

PrimaryPFS(Progression Free Survival)

PFS was defined as the time from randomization to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS according to RECIST 1.1 as assessed by BIRRC was reported for each arm.

Time frame:
Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)
Reported as:
Median · months
PFS(Progression Free Survival)
monthsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
PFS(Progression Free Survival)5.5 (4.9 to 6.8)4.9 (4.8 to 5.0)
SecondaryOS (Overall Survival)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. OS was reported for each arm.

Time frame:
Through Database Cutoff Date of 15 October 2019 (up to approximately 13 months)
Reported as:
Median · Months
OS (Overall Survival)
MonthsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
OS (Overall Survival)NA (NA to NA)NA (NA to NA)
SecondaryORR(Objective Response Rate)

ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: disappearance of all lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The percentage of participants who experienced a confirmed CR or PR according to RECIST 1.1 as assessed by BIRRC was reported as the ORR for each arm.

Time frame:
Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)
Reported as:
Number · Percentage of Participants
ORR(Objective Response Rate)
Percentage of ParticipantsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
ORR(Objective Response Rate)44.7 (37.27 to 52.29)35.4 (28.38 to 42.90)
SecondaryTTR (Time to Response)

TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR (disappearance of all lesions) or PR (at least a 30% decrease in the sum of diameters \[SOD\] of target lesions, taking as reference the baseline SOD) according to RECIST 1.1. The time from first treatment administration to the first incidence of treatment response was reported as the TTR for each arm.

Time frame:
Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)
Reported as:
Median · Months
TTR (Time to Response)
MonthsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
TTR (Time to Response)1.41 (1.2 to 11.1)1.41 (1.2 to 2.9)
SecondaryDCR (Disease Control Rate)

DCR was defined as the percentage of participants who had a CR (disappearance of all target lesions), PR (at least a 30% decrease in the sum of diameters of target lesions), or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \[PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD\]). The percentage of participants who experienced a confirmed CR, PR, or SD according to RECIST 1.1 as assessed by BIRRC was reported as the DCR for each arm.

Time frame:
Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)
Reported as:
Number · Percentage of Participants
DCR (Disease Control Rate)
Percentage of ParticipantsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
DCR (Disease Control Rate)86.0 (80.08 to 90.75)80.3 (73.73 to 85.91)
SecondaryDOR (Duration of Response)

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death. DOR for participants who had not progressed or died at the time of analysis was censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BIRRC assessment. The DOR according to RECIST 1.1 for all participants who experienced a confirmed CR or PR was reported for each arm.

Time frame:
Through Database Cutoff Date of 25 March 2020 (up to approximately 18 months)
Reported as:
Median · Months
DOR (Duration of Response)
MonthsSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
DOR (Duration of Response)6.05 (4.73 to 9.63)5.06 (3.71 to 5.55)

Adverse events

Collected over Through database cutoff date of 25 March 2020 (up to approximately 18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sintilimab+ Gemcitabine Plus Platinum65/179 (36.3%)90/179 (50.3%)179/179 (100%)
Placebo+Gemcitabine Plus Platinum71/178 (39.9%)80/178 (44.9%)178/178 (100%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
Platelet count decreasedInvestigations32/17932/178
PneumoniaInfections and infestations22/17914/178
White blood cell count decreasedInvestigations7/1798/178
HaemoptysisRespiratory, thoracic and mediastinal disorders8/1794/178
AnaemiaBlood and lymphatic system disorders6/1796/178
Neutrophil count decreasedInvestigations5/1795/178
DeathGeneral disorders2/1795/178
PyrexiaGeneral disorders5/1793/178
RashSkin and subcutaneous tissue disorders5/1790/178
PneumonitisRespiratory, thoracic and mediastinal disorders4/1791/178
Most frequent other events
Showing 10 of 55
Most frequent other events
EventSintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus Platinum
AnaemiaBlood and lymphatic system disorders167/179161/178
White blood cell count decreasedInvestigations159/179153/178
Neutrophil count decreasedInvestigations149/179146/178
Platelet count decreasedInvestigations130/179125/178
NauseaGastrointestinal disorders71/17973/178
VomitingGastrointestinal disorders58/17961/178
AstheniaGeneral disorders60/17960/178
Decreased appetiteMetabolism and nutrition disorders57/17953/178
ConstipationGastrointestinal disorders55/17945/178
PyrexiaGeneral disorders52/17947/178

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus PlatinumTotal
Mean61.9 ± 7.4761.0 ± 7.8561.5 ± 7.66
Sex: Female, Male
Sex: Female, Male(Participants)Sintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus PlatinumTotal
Female161430
Male163164327
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus PlatinumTotal
Hispanic or Latino000
Not Hispanic or Latino179178357
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus PlatinumTotal
American Indian or Alaska Native000
Asian179178357
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Sintilimab+ Gemcitabine Plus PlatinumPlacebo+Gemcitabine Plus PlatinumTotal
China179178357
08

Study locations

1 site
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai 200433, China
09

References and documents

Publications

  • Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, Zhou J, Zhou C, Li B, Li J, Fan M, Cui J, Li Y, Zhao H, Fang J, Xue J, Hu C, Sun P, Du Y, Zhou H, Wang S, Zhang W. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25. PubMed 34048947 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Mar 2020, 17 months.

Results were first posted in Apr 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 14, 2018
StartActual
Sep 28, 2018
Primary completionActual
Mar 25, 2020
CompletionActual
Sep 30, 2021
Results first posted
Apr 1, 2021
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03629925
Responsible party
Sponsor
First posted
Aug 14, 2018
Start date
Sep 28, 2018
Primary completion
Mar 25, 2020
Completion
Sep 30, 2021
Results posted
Apr 1, 2021
Last update
Feb 28, 2023

Study contacts

Caicun Zhou
principal investigator · Shanghai Pulmonary Hospital, Shanghai, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion